Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
ACET Quote, Financials, Valuation and Earnings
Last price:
$7.54
Seasonality move
:
-17.45%
Day range:
$6.67 - $7.13
52-week range:
$6.41 - $17.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.50x
P/B ratio:
0.62x
Volume:
111.4K
Avg. volume:
176.6K
1-year change:
-48.24%
Market cap:
$67.4M
Revenue:
--
EPS (TTM):
-$1.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACET
Adicet Bio, Inc.
|
-- | -$2.99 | -- | -843.62% | $69.80 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.70 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$230.8M | -$0.37 | -87.74% | -73.49% | $81.36 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACET
Adicet Bio, Inc.
|
$7.02 | $69.80 | $67.4M | -- | $0.00 | 0% | 1.50x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.50 | $31.70 | $3.8B | 9.83x | $0.00 | 0% | 3.56x |
|
AGEN
Agenus, Inc.
|
$3.18 | $12.33 | $114.9M | -- | $0.00 | 0% | 0.80x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.65 | $457.00 | $42.3B | 141.18x | $0.00 | 0% | 11.45x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$64.10 | $81.36 | $9B | 41.67x | $0.00 | 0% | 8.08x |
|
SVRA
Savara, Inc.
|
$5.58 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACET
Adicet Bio, Inc.
|
12.46% | 2.046 | 1.44% | 5.44x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
AGEN
Agenus, Inc.
|
510.35% | 3.128 | 285.06% | 0.03x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
54.75% | 3.931 | 7.54% | 3.27x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACET
Adicet Bio, Inc.
|
-$1.6M | -$28M | -65% | -71.7% | -- | -$22.5M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$257.6M | $40.8M | 19.23% | 50.21% | 15.46% | $11.3M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Adicet Bio, Inc. vs. Competitors
-
Which has Higher Returns ACET or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Adicet Bio, Inc.'s net margin of 96.33%. Adicet Bio, Inc.'s return on equity of -71.7% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital ACETAdicet Bio, Inc.-- -$0.29 $124.7M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About ACET or ACAD?
Adicet Bio, Inc. has a consensus price target of $69.80, signalling upside risk potential of 776.07%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.70 which suggests that it could grow by 40.89%. Given that Adicet Bio, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Adicet Bio, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACETAdicet Bio, Inc.7 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is ACET or ACAD More Risky?
Adicet Bio, Inc. has a beta of 1.557, which suggesting that the stock is 55.685% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock ACET or ACAD?
Adicet Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adicet Bio, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACET or ACAD?
Adicet Bio, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Adicet Bio, Inc.'s net income of -$26.9M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Adicet Bio, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adicet Bio, Inc. is 1.50x versus 3.56x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACETAdicet Bio, Inc.1.50x -- -- -$26.9M ACADACADIA Pharmaceuticals, Inc.3.56x 9.83x $284M $273.6M
-
Which has Higher Returns ACET or AGEN?
Agenus, Inc. has a net margin of -- compared to Adicet Bio, Inc.'s net margin of -116.82%. Adicet Bio, Inc.'s return on equity of -71.7% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ACETAdicet Bio, Inc.-- -$0.29 $124.7M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About ACET or AGEN?
Adicet Bio, Inc. has a consensus price target of $69.80, signalling upside risk potential of 776.07%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 287.84%. Given that Adicet Bio, Inc. has higher upside potential than Agenus, Inc., analysts believe Adicet Bio, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACETAdicet Bio, Inc.7 0 0 AGENAgenus, Inc.2 1 0 -
Is ACET or AGEN More Risky?
Adicet Bio, Inc. has a beta of 1.557, which suggesting that the stock is 55.685% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.
-
Which is a Better Dividend Stock ACET or AGEN?
Adicet Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adicet Bio, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACET or AGEN?
Adicet Bio, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Adicet Bio, Inc.'s net income of -$26.9M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Adicet Bio, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adicet Bio, Inc. is 1.50x versus 0.80x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACETAdicet Bio, Inc.1.50x -- -- -$26.9M AGENAgenus, Inc.0.80x -- $30.2M $63.9M
-
Which has Higher Returns ACET or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Adicet Bio, Inc.'s net margin of 16.99%. Adicet Bio, Inc.'s return on equity of -71.7% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital ACETAdicet Bio, Inc.-- -$0.29 $124.7M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About ACET or ALNY?
Adicet Bio, Inc. has a consensus price target of $69.80, signalling upside risk potential of 776.07%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 43.42%. Given that Adicet Bio, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Adicet Bio, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACETAdicet Bio, Inc.7 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is ACET or ALNY More Risky?
Adicet Bio, Inc. has a beta of 1.557, which suggesting that the stock is 55.685% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock ACET or ALNY?
Adicet Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adicet Bio, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACET or ALNY?
Adicet Bio, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Adicet Bio, Inc.'s net income of -$26.9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Adicet Bio, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adicet Bio, Inc. is 1.50x versus 11.45x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACETAdicet Bio, Inc.1.50x -- -- -$26.9M ALNYAlnylam Pharmaceuticals, Inc.11.45x 141.18x $1.1B $186.4M
-
Which has Higher Returns ACET or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -- compared to Adicet Bio, Inc.'s net margin of 10.7%. Adicet Bio, Inc.'s return on equity of -71.7% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21%.
Company Gross Margin Earnings Per Share Invested Capital ACETAdicet Bio, Inc.-- -$0.29 $124.7M ARWRArrowhead Pharmaceuticals, Inc.97.58% $0.22 $1.3B -
What do Analysts Say About ACET or ARWR?
Adicet Bio, Inc. has a consensus price target of $69.80, signalling upside risk potential of 776.07%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.36 which suggests that it could grow by 26.93%. Given that Adicet Bio, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Adicet Bio, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACETAdicet Bio, Inc.7 0 0 ARWRArrowhead Pharmaceuticals, Inc.7 3 0 -
Is ACET or ARWR More Risky?
Adicet Bio, Inc. has a beta of 1.557, which suggesting that the stock is 55.685% more volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.681%.
-
Which is a Better Dividend Stock ACET or ARWR?
Adicet Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adicet Bio, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACET or ARWR?
Adicet Bio, Inc. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $264M. Adicet Bio, Inc.'s net income of -$26.9M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M. Notably, Adicet Bio, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is 41.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adicet Bio, Inc. is 1.50x versus 8.08x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACETAdicet Bio, Inc.1.50x -- -- -$26.9M ARWRArrowhead Pharmaceuticals, Inc.8.08x 41.67x $264M $28.2M
-
Which has Higher Returns ACET or SVRA?
Savara, Inc. has a net margin of -- compared to Adicet Bio, Inc.'s net margin of --. Adicet Bio, Inc.'s return on equity of -71.7% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital ACETAdicet Bio, Inc.-- -$0.29 $124.7M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About ACET or SVRA?
Adicet Bio, Inc. has a consensus price target of $69.80, signalling upside risk potential of 776.07%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 93.77%. Given that Adicet Bio, Inc. has higher upside potential than Savara, Inc., analysts believe Adicet Bio, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACETAdicet Bio, Inc.7 0 0 SVRASavara, Inc.6 0 0 -
Is ACET or SVRA More Risky?
Adicet Bio, Inc. has a beta of 1.557, which suggesting that the stock is 55.685% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock ACET or SVRA?
Adicet Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adicet Bio, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACET or SVRA?
Adicet Bio, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Adicet Bio, Inc.'s net income of -$26.9M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Adicet Bio, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adicet Bio, Inc. is 1.50x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACETAdicet Bio, Inc.1.50x -- -- -$26.9M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
